Extreme Transformation Of Simon Lafontant (Credit-goliath_gg/Instagram)
We often see celebrities go through weight loss transformations, with side-by-side comparisons of the before and after weight loss. But people often do not feel inspired or drawn to their stories as we all know that they have access to great personal trainers, high-end food products as well as better access to healthcare. But one story that was highlighted by Men’s Health in their ‘First Steps’ series can inspire many with the story of Simon Lafontant, who lost 150 pounds and went on to become a body builder.
Simon Lafontant, a 32-year-old from Calgary, had to deal with some serious health problems for a long time. These included low testosterone and Crohn's disease, which made his life difficult. But Simon decided he wanted to make a change. He got medical help for his low testosterone and then set a big goal for himself: to compete in a bodybuilding competition. He used social media to keep himself on track, and he ended up losing over 150 pounds and even winning the competition! His story is about how he went from struggling with his health to becoming a bodybuilding champion.
Simon talks about how he used to have bad habits and wasn't living a healthy lifestyle. This led to him feeling down, gaining weight, and losing motivation. Things got really serious in 2020 when his Crohn's disease caused him to be in the hospital for seven whole months. According to Mayo Clinic Crohn’s disease is a type of inflammatory bowel disease that is inflammation in your digestive tract which can be very painful and can cause people to need long term remission and time to heal the inflammation. Simon spoke about how he realized his poor lifestyle choices and being obese had made his symptoms worse!
While you may not wish to become a bodybuilder, there are many other aspects you can take away from the Simon’s story! Another trip to the doctors revealed that he had very low testosterone levels, which explained his lack of energy. This was a major turning point for him, as he finally understood some of the reasons behind his struggles.
One thing that made a huge difference in Simon’s weight loss journey was getting the TRT treatment for his low testosterone which had an almost immediate effect on him. He felt good, started enjoying things again, like going outside and working out. He also remembered how much he loved powerlifting and Strongman competitions, so this helped him get on to his path to bodybuilding and weight training!
Low testosterone affects both men and women, but in different ways. In women, it can cause low sex drive, tiredness, muscle weakness, trouble getting pregnant, irregular periods, vaginal dryness, mood changes like depression or anxiety, hair thinning, dry skin, and sleep problems. In men, low testosterone can lead to reduced sex drive, erectile dysfunction, hair loss, smaller testicles, hot flashes, and infertility. Other symptoms in men include feeling down, trouble concentrating or remembering things, and increased body fat. If you're experiencing any of these symptoms, it's a good idea to talk to a doctor.
Image credits: Canva
Alzheimer's disease is one of the most prevalent types of dementia, and one of the biggest challenges is that the disease can begin many years before symptoms such as memory loss, confusion, or difficulty performing daily activities become noticeable. By the time these signs appear, important changes may have already occurred in the brain.
New hope comes from recent advances in diagnostic technologies. Scientists are developing specialized brain imaging techniques that can detect changes associated with Alzheimer's disease long before symptoms develop. These scans can identify abnormal protein deposits, such as amyloid and tau, which are known to play a key role in the disease process. Early identification of these changes may help doctors monitor individuals more closely and initiate timely interventions.
In addition to brain imaging, blood-based biomarkers are emerging as a promising tool for Alzheimer's screening. Recent research has shown that certain proteins linked to Alzheimer's disease can be detected through simple blood tests. While these tests are not yet a replacement for comprehensive evaluation, they may help identify individuals who require further assessment and could make early screening more accessible and affordable in the future.
These advanced tests are not currently recommended as routine screening for everyone, but they represent a significant step forward in early diagnosis and personalized care. Early detection may allow individuals to make informed life decisions, manage risk factors such as diabetes, hypertension, high cholesterol, and obesity, and potentially benefit from newer treatments that are most effective in the early stages before significant brain damage occurs.
Also Read: FSSAI Targets 6 Energy Drink Brands; Experts Link Them to Obesity, Liver Problems
Prevention, early detection, and timely intervention are the keys to the future of Alzheimer's care. As science advances, innovative imaging techniques and blood-based tests could help shift the focus from managing symptoms to identifying risk earlier and preserving quality of life. Early awareness and proactive brain health management remain our strongest tools in the fight against Alzheimer's disease.
Dr. Aparna Gupta, Director, Neurology, ISIC Multispeciality Hospital
Credit: iStock
Vitiligo is an acquired disorder of depigmentation characterized by white patches on the body. It affects all races. There is a lot of stigma associated with the disease due to disfigurement. The affected persons suffer from psychological distress, low self-esteem, and social neglect. Inadequate knowledge and age-old misconceptions are the key reasons for this undue apprehension associated with this condition.
Common Myths About Vitiligo
There is a misconception that vitiligo can spread by contact. However, vitiligo is non-contagious and does not spread by contact.
Another misconception is that sour food causes vitiligo, which is not scientifically proven. It cannot be transmitted through contact, shared items, or proximity. It is not caused by bacterial, viral, or other infectious agents. It tends to be more noticeable in people with darker skin, due to higher contrast between affected and unaffected areas.
There is no significant variation in people of different races, religions, and socio-economic status for predisposition to vitiligo. There is another myth that vitiligo and leprosy are the same, as both present with white skin.
The exact cause is multifactorial, with hypotheses based on genetic—autoimmune, neural, and biochemical theories. There is a role of acquired factors like stress and infections in its clinical expression. It is associated with other autoimmune disorders like diabetes mellitus, alopecia areata, Addison's disease, and thyroid disorders.
The course of the disease is unpredictable. If you notice any skin discoloration, reach out to a dermatologist for early diagnosis and treatment.
Bust the myths about vitiligo with proper information regarding the condition.
By proper public awareness, the social stigma associated with the condition can be debunked. A qualified dermatologist can diagnose the condition with medical history, Wood's lamp examination, and blood tests to rule out other autoimmune diseases.
There is no cure for vitiligo, but treatment to restore pigmentation and to prevent progression of the disease can be done. Counseling and support groups to help patients with this disorder can make a meaningful difference.
(Dr. Saji Firoz, Consultant, Dermatology & Cosmetology, KIMSHEALTH, Thiruvananthapuram)
Credit: iStock
Fentanyl is an FDA-approved, quick-acting narcotic painkiller that is nearly 100 times more potent than morphine and 50 times stronger than heroin. While it has important medical uses, widespread illicit use has created a public health crisis, with researchers now warning that commonly used addiction treatments are struggling to keep pace.
A study by researchers at the University of California, Los Angeles, found that people who regularly use illicit fentanyl consume opioid doses equivalent to morphine levels hundreds of times higher than the fentanyl doses used in hospitals—far beyond what current addiction treatment protocols were designed to address.
Published in the journal Drug and Alcohol Dependence, the findings suggest these extreme exposure levels contribute to high opioid tolerance, making medications for opioid use disorder (MOUD) less effective and increasing overdose risk.
Although methadone and buprenorphine remain highly effective at reducing overdose deaths, many patients have struggled to start and remain on treatment since fentanyl replaced heroin as the dominant illicit opioid in the US because of the severity of fentanyl withdrawal, the team said.
The researchers estimated fentanyl exposure using morphine milligram equivalence (MME), a standardized measure that compares the potency of different opioids.
The analysis combined purity data from more than 500 fentanyl samples collected by Drug Checking Los Angeles between September 2023 and January 2026 with surveys of 47 people who regularly used fentanyl.
The researchers estimated that participants consumed an average of 8,887 MME per day.
According to the US Centers for Disease Control and Prevention (CDC), just 2 mg of fentanyl can be lethal for an opioid-naïve person. The study found that the average fentanyl user in Los Angeles consumes roughly 60 times that amount each day.
Tolerance develops not only to the drug's intoxicating effects but also to the respiratory depression that causes overdose, said Dr. Chelsea Shover, associate professor in the Department of Health Policy and Management.
"Now, we find that people are regularly exposed to doses of opioids that would have seemed impossible to me before I started this work," Shover said.
"To put it in perspective, in hospital settings, fentanyl is often dosed in 100-microgram vials. One gram of average-purity fentanyl that we tested had a dose equivalent to more than 1,200 of these vials. So people are getting daily doses that are on par with injecting hundreds of the hospital vials or taking 440 Percocet pills."
According to the researchers, the potency and variability of illicit fentanyl mean that people are consuming opioid doses far beyond what existing treatment protocols were designed to manage.
"Of course, starting MOUD is going to be harder for fentanyl than it is for heroin," Shover said.
"This study is a great example of where our science was directly informed by lived experience. It is a call to take withdrawal management seriously, with adjuvant therapies, and compassionate approaches."
As a fully synthetic drug, fentanyl is cheaper and easier to produce than heroin. Its high potency also increases the risk of unintentionally consuming dangerous amounts, raising the likelihood of overdose.
"It's no longer, 'how do we treat someone who smokes a gram of fentanyl per day,' it's 'how do we treat someone using thousands of MMEs of oral morphine in fentanyl per day?' That question and its answers feel more accessible, less abstract to clinicians," Shover said.
The study reinforces concerns among addiction experts that standard treatment regimens for opioid addiction may no longer adequately address patients with extremely high fentanyl tolerance.
Current doses of medications such as buprenorphine and methadone were originally developed to treat heroin and prescription opioid addiction. The findings add to growing calls from clinicians to update treatment guidelines to reflect today's illicit fentanyl market.
"When patients say their withdrawal is not being treated well, it's important to listen," Shover said.
© 2024 Bennett, Coleman & Company Limited